

**Question for written answer E-003115/2022
to the Commission**
Rule 138
Christine Anderson (ID)

Subject: Advance purchase agreements (APAs) with vaccine manufacturers

In anticipation of the COVID-19 vaccine orders, the Commission concluded 'Advanced purchase agreements' (APAs) with pharmaceutical companies.

1. What payments did vaccine manufacturers receive under such APAs?
2. To what extent were these payments offset against subsequent orders (i.e. as a kind of 'advance') or did these payments constitute financial support without any subsequent offsetting?
3. To what extent were payments made to pharmaceutical companies that subsequently did not place a vaccine on the market?